| Study | Population | Intervention | Comparison | Details of inadequate response/treatment resistance | Comments |
|---|---|---|---|---|---|
|
RCT Europe & Australia |
N=406 Mean age (years): 42.5 Gender (% female): 67 Ethnicity (% BME): NR Baseline severity: MADRS 30.9 (more severe) | Venlafaxine extended release 75-300mg/day | Citalopram 20-60mg/day | Inadequate response following 8 weeks of monotherapy with an adequate dosing regimen of an SSRI other than citalopram |
Treatment length (weeks): 12 Outcomes:
|
|
RCT France |
N=123 Mean age (years): 43.3 Gender (% female): 72 Ethnicity (% BME): NR Baseline severity: HAMD 24.6 (more severe) | Venlafaxine 65-300mg/day | Paroxetine 20-40mg/day | TRD: History of resistance to 2 previous successive antidepressant treatments for the current episode (except venlafaxine or paroxetine) |
Treatment length (weeks): 4 Outcomes:
|
|
RCT US |
N=488 Mean age (years): 41.8 Gender (% female): 60 Ethnicity (% BME): 24 Baseline severity: QIDS 13.2 (more severe) | Venlafaxine extended release 37.5-375mg/day | Sertraline 50-200mg/day | Inadequate response (not achieved remission or who were intolerant [56%]) to an initial prospective treatment with citalopram |
Treatment length (weeks): ≤14 Outcomes:
|
BME: black and minority ethnic; HAMD: Hamilton depression scale; MADRS: Montgomery-Asberg depression rating scale; NR: not reported; QIDS: quick inventory of depressive symptomatology; RCT: randomised controlled trial; SNRI: serotonin-norepinephrine reuptake inhibitors; SSRI: selective serotonin reuptake inhibitor; TRD: treatment-resistant depression
From: Further-line treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.